Distortion-product otoacoustic emission: Early detection in deferoxamine induced ototoxicity

Auris Nasus Larynx

Volumn 35, Issue 2, 2008, Pages 198-202

  Delehaye, Emilio ^a   Capobianco, Saverio ^a   Bertetto, Ivano Bruno ^a   Meloni, Francesco ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Deferoxamine; Distortion product otoacoustic emissions; Ototoxicity; Pure tone audiometry

Indexed keywords

DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; AUDIOLOGY; BETA THALASSEMIA; DISTORTION PRODUCT OTOACOUSTIC EMISSION; FEMALE; HUMAN; INTERMETHOD COMPARISON; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; OTOTOXICITY; PURE TONE AUDIOMETRY; SCHOOL CHILD;

ADOLESCENT; ADULT; ALEXIA, PURE; BETA-THALASSEMIA; CHILD; DEFEROXAMINE; FEMALE; HUMANS; MALE; OTOACOUSTIC EMISSIONS, SPONTANEOUS;

EID: 41549109251     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2007.05.001     Document Type: Article

References (17)

1. Chen S.H., Liang D.C., Lin H.C., Cheng S.Y., Chen L.J., and Liu H.C. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. J Pediatr Hematol Oncol 27 December (12) (2005) 651-653
2. Kontzoglou G., Koussi A., Economou M., Tsatra I., Perifanis V., Noussios G., and Athanassiou-Metaxa M. Long term audiological evaluation of beta-thalassemic patients. Acta Otorhinolaryngol Belg 58 2 (2004) 113-117
3. Karimi M., Asadi-Pooya A.A., Khademi B., Asadi-Pooya K., and Yarmohammadi H. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine. Acta Haematol 108 2 (2002) 79-83
4. Ambrosetti U., Donde E., Piatti G., and Cappellini M. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. Pharmacol Res 42 November (5) (2000) 485-487
5. Brownell W.E. Outer hair cell electromotility and otoacustic emissions. Ear Hear 11 (1990) 82-92
6. Probst R. A review of otoacoustic emissions. J Acoust Soc Am 89 (1991) 2027-2067
7. Franklin D.J., McCoy M.J., Martin O.K., and Lonsbury B.L. Test/retest reliability of distortion-product and transiently evoked otoacoustic emissions. Ear Hear 13 (1992) 417-429
8. Stavroulaki P., Apostolopoulos N., Dinopoulou D., Vossinakis I., Tsakanikos M., and Douniadakis D. Otoacoustic emissions-an approach for monitoring aminoglycoside induced ototoxicity in children. Int J Paediatr Oto Rhino Laryngol 50 (1999) 177-184
9. Hotz M.A., Harris F.P., and Probst R. Otoacoustic emissions: an approach for monitoring aminoglicoside-induced ototoxicity. Laryngoscope 104 (1994) 1130-1134
10. Wilbur L.A. Pure tone audiometry: air and bone conduction. In: Rintelmann W.F. (Ed). Hearing assessment. 2nd ed. (1991), Pro-ed, Austin 1-38
11. Lonsbury B.B., Harris F.P., Stagner B., Hawkins M.D., and Martin O.K. Distortion product emissions in humans: basic properties in normally hearing subjects. Ann Otol Rhinol Laryngol 147 Suppl. (1990) 993-1014
12. Ambrosetti U., Donde E., Piatti G., and Cappellini M.D. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. Pharmacol Res 42 November (5) (2000) 485-487
13. Giardina P.J., and Grady R.W. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol 32 October (4) (1995) 304-312
14. Arnold D.J., Lonsbury-Martin B.L., and Martin O.K. High-frequency hearing influences lower-frequency distortion product otoacoustic emissions. Arch Otolaryngol Head Neck Surg 25 (1999) 215-222
15. Barron S.E., and Daigneault E.A. Effect of cisplatin on hair cell morphology and lateral wall Na K-ATPase activity. Hear Res 26 February (1987) 131-137
16. Stavroulaki P., Apostolopoulos N., Segas J., Tsakanikos M., and Adamopoulos G. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 59 February (2001) 47-57
17. Bradford D.R., Kasi S., Thomas J.B., and Geoffrey M.W. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Otolaryngol Head Neck Surg 121 December (6) (1999) 694-701